Project Grant R33HL167848
Award Date
9/1/24
Completion Date
6/30/28
Dollars Obligated
$2.4M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $742,984 to support a Phase II clinical trial testing whether the drug empagliflozin can improve right ventricular function in patients with pulmonary arterial hypertension (PAH). The 3-center, blinded, placebo-controlled trial will assess changes in right ventricular ejection fraction and other secondary outcomes over 24 weeks. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the VPS34 protein in the development and progression of pulmonary arterial hypertension (PAH). The $491,056.01 award, effective May 20, 2025 through April 30, 2028, aims to examine the regulation and function of VPS34 in PAH, determine its impact on proliferation and survival of pulmonary artery...
This $102,932 federal Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify clinically accessible metrics that can serve as surrogates for right ventricular-pulmonary arterial (RV-PA) coupling and indicators of RV adaptation in pulmonary arterial hypertension (PAH). The proposed research aims to: 1) develop a multivariable model to identify clinically available metrics as...
The National Heart Lung and Blood Institute (NHLBI) awarded a $164,700 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to study the role of mTOR hyperactivation in pulmonary vascular remodeling. The research aims to examine how mTOR activation in specific mesenchymal cell populations alters endothelial cell behavior and function, and how aberrant mTOR...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $455,826 to conduct a double-blind, randomized, placebo-controlled trial to determine the effects of chronic sildenafil administration on vascular remodeling during left ventricular assist device (LVAD) support. The study aims to assess the impact of sildenafil, a phosphodiesterase-5 inhibitor, on aortic stiffness, carotid...
This Cooperative Agreement awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $866,246 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct a randomized, triple-masked clinical trial evaluating the effects of the drug empagliflozin on right ventricular function and other outcomes in patients with pulmonary arterial hypertension. The 12-month project aims to determine if...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $522,794 to the University of Illinois to conduct research on the role of the voltage-gated proton channel HV1 in the development of pulmonary hypertension. The project aims to use transgenic mice and in vivo approaches to delineate HV1's contributions to pulmonary hypertension pathogenesis, examine the molecular mechanisms, and...
This $2,130,422 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund a comprehensive evaluation of lean muscle mass in patients with pulmonary arterial hypertension (PAH). The research aims to: 1) characterize the endophenotype and metabolomic signature of PAH patients with low lean mass, 2) understand the role of epicardial adipose tissue, 3) assess the impact of low lean mass on patient...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $117,000 to conduct secondary analysis of 3D echocardiography images to compute 3D surface strain of the right ventricle. The goal is to develop computational methods that enable routine spatial and temporal examination of 3D strains using machine learning, and compare these novel 3D strain parameters to disease outcomes in...
This $245,626 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) aims to validate lipidomic signatures related to right ventricular and pulmonary vascular dysfunction in patients with or at risk for pulmonary vascular disease. The research, conducted by The Johns Hopkins University, seeks to: 1) validate lipidomic signatures in the larger, multi-center PVDOMICS cohort and investigate...